Duchenne and Becker Muscular Dystrophies' Prevalence in MD STARnet Surveillance Sites: An Examination of Racial and Ethnic Differences
- PMID: 33477152
- PMCID: PMC8045764
- DOI: 10.1159/000512647
Duchenne and Becker Muscular Dystrophies' Prevalence in MD STARnet Surveillance Sites: An Examination of Racial and Ethnic Differences
Abstract
Introduction: Previous studies indicated variability in the prevalence of Duchenne and Becker muscular dystrophies (DBMD) by racial/ethnic groups. The Centers for Disease Control and Prevention's (CDC) Muscular Dystrophy Surveillance, Tracking, and Research network (MD STARnet) conducts muscular dystrophy surveillance in multiple geographic areas of the USA and continues to enroll new cases. This provides an opportunity to continue investigating differences in DBMD prevalence by race and ethnicity and to compare the impact of using varying approaches for estimating prevalence.
Objective: To estimate overall and race/ethnicity-specific prevalence of DBMD among males aged 5-9 years and compare the performance of three prevalence estimation methods.
Methods: The overall and race/ethnicity-specific 5-year period prevalence rates were estimated with MD STARnet data using three methods. Method 1 used the median of 5-year prevalence, and methods 2 and 3 calculated prevalence directly with different birth cohorts. To compare prevalence between racial/ethnic groups, Poisson modeling was used to estimate prevalence ratios (PRs) with non-Hispanic (NH) whites as the referent group. Comparison between methods was also conducted.
Results: In the final population-based sample of 1,164 DBMD males, the overall 5-year prevalence for DBMD among 5-9 years of age ranged from 1.92 to 2.48 per 10,000 males, 0.74-1.26 for NH blacks, 1.78-2.26 for NH whites, 2.24-4.02 for Hispanics, and 0.61-1.83 for NH American Indian or Alaska Native and Asian or Native Hawaiian or Pacific Islander (AIAN/API). The PRs for NH blacks/NH whites, Hispanics/NH whites, and NH AIAN/API/NH whites were 0.46 (95% CI: 0.36-0.59), 1.37 (1.17-1.61), and 0.61 (0.40-0.93), respectively.
Conclusions: In males aged 5-9 years, compared to the prevalence of DBMD in NH whites, prevalence in NH blacks and NH AIAN/API was lower and higher in Hispanics. All methods produced similar prevalence estimates; however, method 1 produced narrower confidence intervals and method 2 produced fewer zero prevalence estimates than the other two methods.
Keywords: Duchenne-Becker muscular dystrophy; Epidemiology; Race/ethnicity.
© 2021 S. Karger AG, Basel.
Conflict of interest statement
Disclosure Statement
The authors have no conflicts of interest to declare.
Figures
Similar articles
-
Prevalence of Duchenne and Becker muscular dystrophies in the United States.Pediatrics. 2015 Mar;135(3):513-21. doi: 10.1542/peds.2014-2044. Epub 2015 Feb 16. Pediatrics. 2015. PMID: 25687144 Free PMC article.
-
Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States.Orphanet J Rare Dis. 2023 Mar 22;18(1):65. doi: 10.1186/s13023-023-02662-0. Orphanet J Rare Dis. 2023. PMID: 36949506 Free PMC article.
-
Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007.MMWR Morb Mortal Wkly Rep. 2009 Oct 16;58(40):1119-22. MMWR Morb Mortal Wkly Rep. 2009. PMID: 19834452
-
Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet.J Pediatr Rehabil Med. 2016;9(1):5-11. doi: 10.3233/PRM-160361. J Pediatr Rehabil Med. 2016. PMID: 26966795 Free PMC article.
-
A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy.Neuromuscul Disord. 2014 Jun;24(6):482-91. doi: 10.1016/j.nmd.2014.03.008. Epub 2014 Mar 22. Neuromuscul Disord. 2014. PMID: 24780148 Review.
Cited by
-
Barriers to diverse clinical trial participation in Duchenne muscular dystrophy: Engaging Hispanic/Latina caregivers and health professionals.Orphanet J Rare Dis. 2024 May 21;19(1):207. doi: 10.1186/s13023-024-03209-7. Orphanet J Rare Dis. 2024. PMID: 38773664 Free PMC article.
-
Assessing the Benefits and Harms Associated with Early Diagnosis from the Perspective of Parents with Multiple Children Diagnosed with Duchenne Muscular Dystrophy.Int J Neonatal Screen. 2024 Apr 15;10(2):32. doi: 10.3390/ijns10020032. Int J Neonatal Screen. 2024. PMID: 38651397 Free PMC article.
-
Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy.Neuroepidemiology. 2023;57(2):90-99. doi: 10.1159/000528962. Epub 2023 Jan 9. Neuroepidemiology. 2023. PMID: 36623491 Free PMC article.
-
Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network.Neuromuscul Disord. 2022 Jun;32(6):468-476. doi: 10.1016/j.nmd.2022.04.008. Epub 2022 Apr 30. Neuromuscul Disord. 2022. PMID: 35597713 Free PMC article.
-
Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance.J Neuromuscul Dis. 2022;9(3):423-436. doi: 10.3233/JND-210746. J Neuromuscul Dis. 2022. PMID: 35466946 Free PMC article.
References
-
- Flanigan KM. Duchenne and Becker muscular dystrophies. Neurologic clinics. 2014;32(3):671–88, viii. - PubMed
-
- Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2(1):90–5. - PubMed
-
- Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Journal of paediatrics and child health. 2015;51(8):759–64. - PubMed
-
- U.S. Department of Health & Human Services NIoH, NCATS. Becker muscular dystrophy 2016 [2019/July/16]. Available from: https://rarediseases.info.nih.gov/diseases/5900/becker-muscular-dystrophy.
Publication types
MeSH terms
Grants and funding
- U01DD001054/ACL/ACL HHS/United States
- U01DD001245/ACL/ACL HHS/United States
- U01 DD000187/DD/NCBDD CDC HHS/United States
- U01DD001120/ACL/ACL HHS/United States
- U01 DD001123/DD/NCBDD CDC HHS/United States
- U01 DD001247/DD/NCBDD CDC HHS/United States
- U01DD001119/ACL/ACL HHS/United States
- U01DD001108/ACL/ACL HHS/United States
- U01 DD001120/DD/NCBDD CDC HHS/United States
- CC999999/ImCDC/Intramural CDC HHS/United States
- U01DD001126/ACL/ACL HHS/United States
- U01DD001244/ACL/ACL HHS/United States
- U01 DD000191/DD/NCBDD CDC HHS/United States
- U01 DD000190/DD/NCBDD CDC HHS/United States
- U01 DD001244/DD/NCBDD CDC HHS/United States
- U01DD001117/ACL/ACL HHS/United States
- U01 DD001117/DD/NCBDD CDC HHS/United States
- U01 DD001126/DD/NCBDD CDC HHS/United States
- U01DD001116/ACL/ACL HHS/United States
- U01 DD001245/DD/NCBDD CDC HHS/United States
- U01DD001123/ACL/ACL HHS/United States
- U01 DD000189/DD/NCBDD CDC HHS/United States
- U01 DD001116/DD/NCBDD CDC HHS/United States
- U01 DD001119/DD/NCBDD CDC HHS/United States
- U01 DD001108/DD/NCBDD CDC HHS/United States
- U01 DD001248/DD/NCBDD CDC HHS/United States
- U01 DD001054/DD/NCBDD CDC HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources

